The Effect of Entacapone on Levodopa Rate of Absorption and Latency to Motor Response in Patients With Parkinson Disease

2008 ◽  
Vol 31 (5) ◽  
pp. 267-271 ◽  
Author(s):  
Manuela Contin ◽  
Paolo Martinelli ◽  
Cesa Scaglione ◽  
Patrizia Avoni ◽  
Fiorenzo Albani ◽  
...  
PLoS ONE ◽  
2020 ◽  
Vol 15 (3) ◽  
pp. e0229729 ◽  
Author(s):  
Mauro Ursino ◽  
Elisa Magosso ◽  
Giovanna Lopane ◽  
Giovanna Calandra-Buonaura ◽  
Pietro Cortelli ◽  
...  

2015 ◽  
Vol 27 (6) ◽  
pp. 1215-1237 ◽  
Author(s):  
Giorgio Tommasi ◽  
Mirta Fiorio ◽  
Jérôme Yelnik ◽  
Paul Krack ◽  
Francesca Sala ◽  
...  

It is solidly established that top–down (goal-driven) and bottom–up (stimulus-driven) attention mechanisms depend on distributed cortical networks, including prefrontal and frontoparietal regions. On the other hand, it is less clear whether the BG also contribute to one or the other of these mechanisms, or to both. The current study was principally undertaken to clarify this issue. Parkinson disease (PD), a neurodegenerative disorder primarily affecting the BG, has proven to be an effective model for investigating the contribution of the BG to different brain functions; therefore, we set out to investigate deficits of top–down and bottom–up attention in a selected cohort of PD patients. With this objective in mind, we compared the performance on three computerized tasks of two groups of 12 parkinsonian patients (assessed without any treatment), one otherwise pharmacologically treated and the other also surgically treated, with that of a group of controls. The main behavioral tool for our study was an attentional capture task, which enabled us to tap the competition between top–down and bottom–up mechanisms of visual attention. This task was suitably combined with a choice RT and a simple RT task to isolate any specific deficit of attention from deficits in motor response selection and initiation. In the two groups of patients, we found an equivalent increase of attentional capture but also comparable delays in target selection in the absence of any salient distractor (reflecting impaired top–down mechanisms) and movement initiation compared with controls. In contrast, motor response selection processes appeared to be prolonged only in the operated patients. Our results confirm that the BG are involved in both motor and cognitive domains. Specifically, damage to the BG, as it occurs in PD, leads to a distinct deficit of top–down control of visual attention, and this can account, albeit indirectly, for the enhancement of attentional capture, reflecting weakened ability of top–down mechanisms to antagonize bottom–up control.


2010 ◽  
Vol 33 (5) ◽  
pp. 254-256 ◽  
Author(s):  
Giovanna Lopane ◽  
Manuela Contin ◽  
Cesa Scaglione ◽  
Fiorenzo Albani ◽  
Agostino Baruzzi ◽  
...  

2009 ◽  
Vol 32 (6) ◽  
pp. 321-325 ◽  
Author(s):  
Nuria López-Ariztegui ◽  
María Angeles Arévalo ◽  
Maria L. de Ceballos ◽  
Francisco Grandas

2015 ◽  
Vol 5 (3) ◽  
pp. 232-240 ◽  
Author(s):  
José-Francisco Rocha ◽  
Joaquim J. Ferreira ◽  
Amílcar Falcão ◽  
Ana Santos ◽  
Roberto Pinto ◽  
...  

2019 ◽  
Vol 12 (2) ◽  
pp. e32
Author(s):  
Ivan Cordon ◽  
María Jesús Nicolás ◽  
Sandra Arrieta ◽  
Manuel Alegre ◽  
Julio Artieda ◽  
...  

2012 ◽  
Vol 35 (1) ◽  
pp. 6-14 ◽  
Author(s):  
Dag Nyholm ◽  
Anders Johansson ◽  
Sten-Magnus Aquilonius ◽  
Elisabeth Hellquist ◽  
Hans Lennernäs ◽  
...  

Neurology ◽  
2017 ◽  
Vol 89 (5) ◽  
pp. 432-438 ◽  
Author(s):  
Roberto Cilia ◽  
Janeth Laguna ◽  
Erica Cassani ◽  
Emanuele Cereda ◽  
Nicolò G. Pozzi ◽  
...  

Objective:To investigate whether Mucuna pruriens (MP), a levodopa-containing leguminous plant growing in all tropical areas worldwide, may be used as alternative source of levodopa for indigent individuals with Parkinson disease (PD) who cannot afford long-term therapy with marketed levodopa preparations.Methods:We investigated efficacy and safety of single-dose intake of MP powder from roasted seeds obtained without any pharmacologic processing. Eighteen patients with advanced PD received the following treatments, whose sequence was randomized: (1) dispersible levodopa at 3.5 mg/kg combined with the dopa-decarboxylase inhibitor benserazide (LD+DDCI; the reference treatment); (2) high-dose MP (MP-Hd; 17.5 mg/kg); (3) low-dose MP (MP-Ld; 12.5 mg/kg); (4) pharmaceutical preparation of LD without DDCI (LD−DDCI; 17.5 mg/kg); (5) MP plus benserazide (MP+DDCI; 3.5 mg/kg); (6) placebo. Efficacy outcomes were the change in motor response at 90 and 180 minutes and the duration of on state. Safety measures included any adverse event (AE), changes in blood pressure and heart rate, and the severity of dyskinesias.Results:When compared to LD+DDCI, MP-Ld showed similar motor response with fewer dyskinesias and AEs, while MP-Hd induced greater motor improvement at 90 and 180 minutes, longer ON duration, and fewer dyskinesias. MP-Hd induced less AEs than LD+DDCI and LD−DDCI. No differences in cardiovascular response were recorded.Conclusion:Single-dose MP intake met all noninferiority efficacy and safety outcome measures in comparison to dispersible levodopa/benserazide. Clinical effects of high-dose MP were similar to levodopa alone at the same dose, with a more favorable tolerability profile.ClinicalTrials.gov identifier:NCT02680977.


Sign in / Sign up

Export Citation Format

Share Document